SCYX SCYNEXIS, Inc.
$3.80▼ -0.26%
Healthcare
Other
Volume 43.2K
Avg Volume (10D) 70.5K
Key Metrics & Fundamentals
Market Cap
$37.81M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.53 - 9.12
% vs 50 MA
-18.08%
% vs 200 MA
-31.70%
RSI-14
36.7
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.42
Free Cash Flow
-$14.89M
Gross Rev
$235,000
Gross Profit
$235,000
EBITDA
-$6.76M
COGS
–
Operating Exp
$8.01M
Operating Income
-$7.78M
EBIT
-$7.78M
Pretax Income
$7.40M
Net Income
$7.40M
EPS (Diluted)
0.63
Price & Volume History
Loading chart…
Recent News
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
GlobeNewswire · Oct 22, 2026 8:00 AM ET
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
GlobeNewswire · Oct 21, 2026 4:05 PM ET
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
GlobeNewswire · Oct 6, 2026 7:30 AM ET
Scynexis stock surges on $214M BARDA contract for SCY-247
Investing.com · Sep 28, 2026 9:58 AM ET
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
InvestorsHub · Sep 28, 2026 8:10 AM ET
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
GlobeNewswire · Sep 28, 2026 7:30 AM ET
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
GlobeNewswire · Sep 22, 2026 8:00 AM ET
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
GlobeNewswire · Sep 15, 2026 8:00 AM ET
SCYNEXIS Names Sanjay Subramanian as CFO
MT Newswires · Sep 10, 2026 8:57 AM ET
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
GlobeNewswire · Sep 10, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SCYX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.